Literature DB >> 18946078

Amelioration of muscular dystrophy by transgenic expression of Niemann-Pick C1.

Michelle S Steen1, Marvin E Adams, Yan Tesch, Stanley C Froehner.   

Abstract

Duchenne muscular dystrophy (DMD) and other types of muscular dystrophies are caused by the loss or alteration of different members of the dystrophin protein complex. Understanding the molecular mechanisms by which dystrophin-associated protein abnormalities contribute to the onset of muscular dystrophy may identify new therapeutic approaches to these human disorders. By examining gene expression alterations in mouse skeletal muscle lacking alpha-dystrobrevin (Dtna(-/-)), we identified a highly significant reduction of the cholesterol trafficking protein, Niemann-Pick C1 (NPC1). Mutations in NPC1 cause a progressive neurodegenerative, lysosomal storage disorder. Transgenic expression of NPC1 in skeletal muscle ameliorates muscular dystrophy in the Dtna(-/-) mouse (which has a relatively mild dystrophic phenotype) and in the mdx mouse, a model for DMD. These results identify a new compensatory gene for muscular dystrophy and reveal a potential new therapeutic target for DMD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946078      PMCID: PMC2613093          DOI: 10.1091/mbc.e08-08-0811

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  45 in total

1.  Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo.

Authors:  G García-Cardeña; P Martasek; B S Masters; P M Skidd; J Couet; S Li; M P Lisanti; W C Sessa
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Increased caveolin-3 levels in mdx mouse muscles.

Authors:  P L Vaghy; J Fang; W Wu; L P Vaghy
Journal:  FEBS Lett       Date:  1998-07-10       Impact factor: 4.124

3.  Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain.

Authors:  V J Venema; H Ju; R Zou; R C Venema
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

4.  Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle.

Authors:  J M Ervasti; K Ohlendieck; S D Kahl; M G Gaver; K P Campbell
Journal:  Nature       Date:  1990-05-24       Impact factor: 49.962

5.  Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins.

Authors:  K S Song; P E Scherer; Z Tang; T Okamoto; S Li; M Chafel; C Chu; D S Kohtz; M P Lisanti
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

6.  Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy.

Authors:  J E Brenman; D S Chao; H Xia; K Aldape; D S Bredt
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

7.  Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase.

Authors:  D S Chao; F Silvagno; D S Bredt
Journal:  J Neurochem       Date:  1998-08       Impact factor: 5.372

8.  Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity.

Authors:  G A Cox; N M Cole; K Matsumura; S F Phelps; S D Hauschka; K P Campbell; J A Faulkner; J S Chamberlain
Journal:  Nature       Date:  1993-08-19       Impact factor: 49.962

9.  Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice.

Authors:  K J Brennan; E C Hardeman
Journal:  J Biol Chem       Date:  1993-01-05       Impact factor: 5.157

10.  Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy.

Authors:  C Minetti; F Sotgia; C Bruno; P Scartezzini; P Broda; M Bado; E Masetti; M Mazzocco; A Egeo; M A Donati; D Volonte; F Galbiati; G Cordone; F D Bricarelli; M P Lisanti; F Zara
Journal:  Nat Genet       Date:  1998-04       Impact factor: 38.330

View more
  2 in total

1.  Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion.

Authors:  Stephanie Duguez; William Duddy; Helen Johnston; Jeanne Lainé; Marie Catherine Le Bihan; Kristy J Brown; Anne Bigot; Yetrib Hathout; Gillian Butler-Browne; Terence Partridge
Journal:  Cell Mol Life Sci       Date:  2013-01-24       Impact factor: 9.261

2.  Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts.

Authors:  Herman Vandenburgh; Janet Shansky; Frank Benesch-Lee; Kirsten Skelly; Janelle M Spinazzola; Yero Saponjian; Brian S Tseng
Journal:  FASEB J       Date:  2009-06-01       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.